Key points are not available for this paper at this time.
Immunosensors have emerged as vital tools in cancer diagnostics, providing simplified and rapid detection of biomarkers that are necessary for timely diagnosis. The objective of using an electrochemical immunosensor is to detect cancers at early stages, so that obtained biological information can be analyzed using artificial intelligence (AI) for deciding an appropriate treatment, avoiding false diagnosis, and preventing patient fatalities. The focus of this article is on four major reproductive cancers—breast, ovarian, cervical, and prostate cancers. Specifically, it explores the identification and optimization of biomarkers crucial for the precise detection of these cancers. Examining a decade of research, the review delves into nanotechnology-assisted electrochemical immunosensors (affinity biosensors), outlining advancements and emphasizing their potential in reproductive cancer diagnostics. Furthermore, the review contemplates avenues for enhancing sensor characteristics to pave the way for their application in field diagnosis, with a forward-looking perspective on AI-assisted diagnostics for the next generation of personalized healthcare. In navigating the landscape of reproductive cancer diagnostics, the integration of advanced technologies promises to transform our approach, offering improved accuracy and outcomes for patients.
Kokilavani et al. (2024) studied this question.